title: United Therapeutics
id: 33089771
United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR It develops novel life extending technologies for patients in the areas of lung disease and organ manufacturing United Therapeutics is co headquartered in Silver Spring Maryland and Research Triangle Park North Carolina with additional facilities in Magog and Bromont Quebec Melbourne and Jacksonville Florida Blacksburg Virginia and Manchester New Hampshire br br br History br United Therapeutics was founded in by Martine Rothblatt an American lawyer author and entrepreneur who created Sirius XM In Rothblatt s young daughter was diagnosed with a fatal orphan disease pulmonary arterial hypertension PAH Rothblatt sold her telecom stock and started the PPH Cure Foundation to fund PAH research br In the U S Food and Drug Administration FDA approved United Therapeutics drug Remodulin a prostacyclin vasodilator used to treat PAH Remodulin provided PAH patients with an alternative to GlaxoSmithKline s Flolan By Remodulin annual sales had reached million By annual sales were million and United Therapeutics share price had increased percent from the initial public offering price br In United Therapeutics acquired Revivicor a company focused on developing genetic biotechnology platforms to provide alternative tissue sources for treatment With the acquisition of Revivicor United Therapeutics began the xenokidney program to find alternative sources of organs for patients awaiting a kidney transplant Xenotransplantation is a potential solution as it possibly could provide a limitless supply of organs br In the company acquired SteadyMed a medical device company developing injectable therapeutic drugs for pulmonary hypertension Other acquisitions include SynQuest in and Cooke Pharma in United Therapeutics has entered numerous licensing agreements and collaborations with companies such as Eli Lilly and Company DEKA Research Development MannKind Corporation and the National Cancer Institute br On January a porcine heart provided by United Therapeutics Revivicor subsidiary in conjunction with the University of Maryland Medical Center was used in the first pig to human transplant operation The recipient subsequently died on March br In October United Therapeutics purchased bioengineering company IVIVA Medical Inc for million plus royalties Sixteen IVIVA employees transferred to United Therapeutics br In December United Therapeutics Corporation completed the acquisition of Miromatrix Medical Inc a biotechnology company that specializes in the development of bioengineered organs composed of human cells br br br Medicines br United Therapeutics products are sold in the U S and Canada and its products are available in Central and South America Europe the Middle East and Asia through various distribution partners In the U S the company has received multiple approvals from the Food and Drug Administration These cover various strengths and routes of administration for Orenitram Remodulin Tyvaso and Tyvaso DPI each indicated for the treatment of pulmonary arterial hypertension Tyvaso and Tyvaso DPI are also indicated for the treatment of pulmonary hypertension associated with interstitial lung disease PH ILD br United Therapeutics also markets Adcirca tadalafil for the treatment of pulmonary arterial hypertension under a licensing agreement with Eli Lilly and Company br In February the U S Food and Drug Administration granted clearance for the Unity Subcutaneous Delivery System for Remodulin Injection also known as the Remunity pump allowing the system to be used with drug cassettes that have been prefilled by specialty pharmacies The Remunity system allows for constant subcutaneous under the skin delivery of Remodulin The Remunity system is indicated for the treatment of pulmonary arterial hypertension in patients older than br In March the U S FDA approved United Therapeutics Biologics License Application BLA for Unituxin Unituxin is a monoclonal antibody used as a second line treatment for children with high risk neuroblastoma a rare form of cancer br In May the U S FDA approved United Therapeutics New Drug Application NDA for Tyvaso DPI Tyvaso DPI is a dry powder inhaler containing treprostinil and is indicated for both PAH and PH ILD br br br Research br United Therapeutics is advancing a pipeline of research and development projects that includes new indications formulations and delivery devices for its existing products The company s R D pipeline includes five registration phase studies primarily in rare lung diseases and seven preclinical product leads primarily in organ manufacturing br In February United Therapeutics reported that it had successfully completed the INCREASE study of Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease PH ILD and that the study met its primary endpoint of demonstrating improvement in six minute walk distance MWD The company submitted the INCREASE study results to the U S Food and Drug Administration in support of an efficacy supplement to the Tyvaso New Drug Application and received approval on March br Ongoing clinical trials of new medicines include ADVANCE OUTCOMES Phase for ralinepag in pulmonary arterial hypertension a registration study of the Centralized Lung Evaluation System and TETON and TETON for idiopathic pulmonary fibrosis IPF br United Therapeutics is developing a unique type of biopharmaceutical medicinal product known as a manufactured organ This type of biologic would be transplanted into the patient as a substitute for a failing organ The company has regenerative medicine products such as these being developed via xenotransplantation allogenic recellularization and autologous bioprinting technologies br In researchers at New York University used a ThymoKidney xenokidney in the first transplant of a genetically engineered nonhuman kidney into a brain dead human body observing kidney function over hours Researchers at The University of Alabama at Birmingham used a UKidney xenokidney in a transplant into a brain dead recipient observing kidney function over hours br In engineers from the company s Unither Bioelectronics subsidiary conducted the first flight of human lungs for transplant from Toronto Western Hospital to Toronto General Hospital The lungs were successfully transplanted into Alain Hodak an engineer from Ottawa Canada br In the UHeart xenoheart was used in the first pig heart to living human transplant The transplanted pig heart had ten genetic modifications to the pig genome br In Martine Rothblatt debuted a D printed lung scaffold that was what she called one of the most complex D printed objects ever printed The printed lung scaffold contained trillion voxels that laid out kilometers of pulmonary capillaries and million pulmonary alveoli br br br Operations br United Therapeutics owns a square foot combination laboratory and office building complex in Silver Spring Maryland The facility serves as the company s co headquarters and is used for commercial manufacturing of active pharmaceutical ingredients and finished dosage form products United Therapeutics also owns a square foot combination manufacturing plant and office building in Research Triangle Park North Carolina The facility serves as the company s co headquarters and is occupied by clinical research and development commercialization logistics manufacturing and packaging personnel Adjacent to its Research Triangle Park complex United Therapeutics owns a acre site containing approximately square feet of building space that is used for research development and manufacturing related to the company s lung regeneration program This site is available for future expansion br United Therapeutics subsidiaries include Lung Biotechnology PBC Lung Bioengineering Inc Miromatrix Medical United Therapeutics Europe Ltd Unither Biotech Inc Canada Unither Pharma LLC Unither Telmed Ltd Unither Bio lectronique Quebec IVIVA Medical and Revivicor Inc As of December United Therapeutics had a global workforce of On June United Therapeutics market capitalization was billion br br br Lung Biotechnology PBC br United Therapeutics subsidiary Lung Biotechnology PBC was the first public benefit corporation subsidiary of a publicly traded biopharmaceutical company Utilizing perfusion Lung Biotechnology pursued innovative technology that could preserve lungs for transplant by stabilizing lungs that would otherwise be discarded The objective was to address the acute shortage of transplantable lungs for patients with end stage lung disease including PAH br br br Corporate social responsibility br In United Therapeutics established a minimum living wage of approximately per year for employees inclusive of incentive pay Fulltime employees are shareholders of the company through United Therapeutics long term incentive programs United Therapeutics has been recognized as one of the Top Corporate Citizens in the field of U S drug manufacturing along with companies such as Amgen Johnson Johnson and Bristol Myers Squibb United Therapeutics was named on Fortune s Best Workplaces in Health Care Biopharma third consecutive year The Washington Post s Top Workplaces for sixth consecutive year Fortune s Best Small Medium Workplaces third consecutive year and Fortune s Best Workplaces for Millennials In United Therapeutics received Women in Technology s Corporate Board Award and was named on Triangle Business Journal s Best Places to Work List for the sixth consecutive year The company was also named to Newsweek s America s Most Responsible Companies list in and br United Therapeutics facilities include one Platinum and two Gold LEED certified buildings as rated by the U S Green Building Council and four net zero buildings located across three states Innovative energy efficient building design multiple solar arrays purchase of renewable energy credits RECs and carbon offsets and other green energy technologies have enabled United Therapeutics to achieve a sustainable urban campus At the time of its construction United Therapeutics site net zero Unisphere a square foot high rise office building in Silver Spring Maryland was the largest urban office building to be energy positive Using extensive solar arrays heat mediating wells and other leading edge design technologies Unisphere generates more energy on site than it consumes br United Therapeutics has implemented corporate governance best practices ahead of industry peers and the Russell These include adopting majority voting and proxy access policies initiating a Board declassification process and imposing a tighter limit on director outside board membership The Board of Directors engages with company shareholders multiple times each year to discuss governance and operations priorities In and United Therapeutics published a comprehensive Corporate Social Responsibility report br In United Therapeutics shareholders approved the conversion of the company into a public benefit corporation PBC As a PBC United Therapeutics while creating value for shareholders must also consider the best interests of those materially affected by the company s conduct and the specific public benefit that it chooses to adopt in its charter PBCs like United Therapeutics are intended to produce public benefits and to operate in a responsible and sustainable manner United Therapeutics public benefit purpose is to provide a brighter future for patients through a the development of novel pharmaceutical therapies and b technologies that expand the availability of transplantable organs br br br Leadership br Martine Aliana Rothblatt founder and chairperson of the board of United Therapeutics graduated from University of California Los Angeles with J D and M B A degrees in In June she earned a Ph D in medical ethics at the Barts and The London School of Medicine and Dentistry Queen Mary University of London Rothblatt worked in Washington D C first in the field of communications satellite law and eventually in life sciences projects like the Human Genome Project She also served as the CEO of GeoStar and the creator of SiriusXM Satellite Radio Michael Benkowitz serves as president and chief operating officer James Edgemond is chief financial officer and treasurer Paul Mahon is general counsel She is also a trans woman br br br 